40 years experience; SVP, Global Sales & Marketing for Digene Corp from IPO to acquisition by QIAGEN NV (in 2007) creating market & technology leader in molecular Dx. Then, Senior Advisor/Molecular Diagnostics for Developing World at QIAGEN. Consultant to John D Rockefeller 3rd Fund, 23andMe, ImpediMed Pty Ltd, Vertex Pharma, OpGen.
Over 25 years’ experience – business and new product development, global commercial and general management in biotechnology. President and CEO of WaferGen Biosystems; President and CEO of Asuragen Inc., a molecular diagnostic company. Vice President for Abbott Laboratories Inc., responsible for business development and licensing. Vice President and General Manager in Molecular Diagnostic Business for Vysis Inc. IVD market over the past 15 years.
35 years experience – medical devices and in-vitro-diagnostics. International roles for Baxter Diagnostics (Australia & UK), Senior Global Marketing Manager for Roche Molecular Systems, and VP Global Strategic Marketing for Digene Corp. Managing Director and CEO for ImpediMed Limited. Boards: StraxCorp, Minomic, UniQuest.
20 years experience – building business strategies, analyzing markets, strategy & transaction consulting, in- and out-licensing and business acquisitions. CEO of Debiopharm Innovation Fund SA. Managing Partner and Director at Innomedica Ltd., serves on the boards of GenePOC as the chair, Kaiku Health and formerly BC Platforms.
15 years experience – medical devices and diagnostics. CEO of CellSeeQ, CEO, COO and Vice President of Operations and Technology at Pronota. Founding scientists and Group Leader of Analytical Department at U.S.-based biotech company Serenex, acquired by Pfizer in 2008. Served on boards as chair of the Center for Medical Innovation and PharmaFluidics.